Quest Diagnostics closed 2025 with a strong fourth quarter, achieving a 7.1% increase in revenues to $2.81 billion and an 11.8% increase in reported diluted EPS to $2.18. For the full year, revenues grew 11.8% to $11.04 billion and reported diluted EPS increased 13.8% to $8.75. The company also announced a 7.5% increase in its quarterly dividend to $0.86 per share and provided optimistic guidance for 2026.

Quest Diagnostics delivered strong third-quarter performance, with revenues up 13.1% to $2.82 billion and adjusted diluted EPS increasing by 13.0% to $2.60. The company's organic growth was 6.8%, driven by clinical innovations and consumer channel expansion. Strategic initiatives, including a new lab services joint venture with Corewell Health and acquisitions, contributed to the positive results, leading to an upward revision of full-year 2025 guidance.

Quest Diagnostics delivered a robust second quarter in 2025, with total revenues reaching $2.76 billion, marking a 15.2% increase year-over-year. Diluted EPS grew by 21.7% to $2.47, and adjusted diluted EPS increased by 11.5% to $2.62. The company also saw a substantial 51.5% rise in cash provided by operations, reaching $544 million for the quarter. This strong performance led Quest Diagnostics to raise its full-year 2025 guidance for both reported and adjusted diluted EPS.

Quest Diagnostics saw a 12.1% increase in revenue and reported a higher net income, driven by acquisitions, enterprise demand, and growth in advanced diagnostics services.

Quest Diagnostics reported a strong Q4 2024, with a 14.5% increase in revenue to $2.62 billion and a 14.7% increase in reported EPS to $1.95. The company's full-year revenue grew by 6.7% to $9.87 billion, and it provided guidance for full-year 2025 with EPS expected to be between $8.34 and $8.59.

Quest Diagnostics reported a strong third quarter with an 8.5% increase in total revenue, including 4.2% organic growth. The company's performance was driven by new customer wins, expanded business with physicians and hospitals, and recent acquisitions. Due to contributions from recent acquisitions, the company has increased its 2024 revenue guidance and has maintained the midpoint of its adjusted EPS guidance despite the impact of Hurricane Milton in the fourth quarter.

Quest Diagnostics reported a 2.5% increase in revenue to $2.40 billion for Q2 2024. Reported EPS decreased slightly by 1.0% to $2.03, while adjusted EPS increased by 2.2% to $2.35. The company has raised its full-year 2024 revenue and EPS guidance.

Quest Diagnostics reported a 1.5% increase in first-quarter revenue to $2.37 billion. Diluted EPS decreased by 3.4% to $1.72, while adjusted diluted EPS was flat at $2.04. The company raised its full-year revenue and adjusted earnings guidance, driven by strong commercial focus, healthcare utilization, and investments in advanced diagnostics and automation.

Quest Diagnostics reported a slight decrease in Q4 revenue by 1.9% year-over-year, totaling $2.29 billion. However, the company saw a significant increase in reported diluted EPS, up 95.4% to $1.70, and an adjusted diluted EPS increase of 8.6% to $2.15. The base business revenues increased by 4.7% to $2.25 billion, while COVID-19 testing revenues decreased by 79.8% to $37 million.

Quest Diagnostics reported a decrease in revenue and EPS for Q3 2023 compared to Q3 2022. Total revenues were $2.30 billion, a 7.7% decrease, while reported EPS was $1.96, a 9.7% decrease. However, base business revenues grew by 4.6%. The company has updated its full-year 2023 guidance, expecting revenues between $9.19 billion and $9.24 billion and adjusted diluted EPS between $8.65 and $8.75.

Quest Diagnostics reported second-quarter revenues of $2.34 billion, a 4.7% decrease year-over-year. However, the company saw a 4.6% increase in reported diluted EPS to $2.05. The base business revenues grew by 9.5% compared to the previous year. The company has updated its full-year 2023 revenue guidance to between $9.12 billion and $9.22 billion and adjusted diluted EPS to between $8.50 and $8.90.

Quest Diagnostics reported a decrease in first quarter revenue by 10.7% compared to 2022, with revenues of $2.33 billion. The decline was driven by an 80.2% decrease in COVID-19 testing revenues, while the base business revenues increased by 10.0%. Reported diluted EPS decreased by 39.0% to $1.78, and adjusted diluted EPS decreased by 36.6% to $2.04.

Quest Diagnostics reported a decrease in revenue by 15.0% and a decrease in EPS by 72.1% for the fourth quarter of 2022. Base business revenues increased by 6.3%, while COVID-19 testing revenues decreased by 74.6%.

Quest Diagnostics reported a decrease in revenue and EPS for Q3 2022 compared to Q3 2021. The decrease was primarily due to a decline in COVID-19 testing revenues. However, the base business revenues increased by 5.1%. The company has raised its outlook for the remainder of 2022 based on this performance.

Quest Diagnostics reported a decrease in revenue and earnings per share for the second quarter of 2022 compared to the previous year, while base business revenues experienced growth. The company has raised its full year guidance based on its performance in the quarter and expectations for the remainder of 2022.

Quest Diagnostics reported a decrease in first-quarter revenue by 4.0% to $2.61 billion, with a diluted EPS of $2.92, down 15.6% compared to the previous year. However, the base business revenues increased by 6.3%. The company raised its full-year 2022 guidance, expecting a reported diluted EPS between $7.88 and $8.38 and an adjusted diluted EPS between $9.00 and $9.50.

Quest Diagnostics reported Q4 2021 financial results, with revenues of $2.74 billion, a decrease of 8.6% compared to Q4 2020. Diluted EPS was $3.12, down 25.9% from 2020, and adjusted diluted EPS was $3.33, down 25.7% from 2020. The company provided full year 2022 guidance and increased its quarterly dividend by 6.5% to $0.66 per share.

Quest Diagnostics reported a slight decrease in revenue and earnings per share for the third quarter of 2021 compared to 2020. However, the company raised its full-year outlook due to higher than anticipated COVID-19 testing volumes and continued solid performance in its base business.

Quest Diagnostics reported a strong second quarter with revenues of $2.55 billion, a 39.5% increase from 2020. Reported diluted EPS was $4.96, up 264.2% from 2020, and adjusted diluted EPS was $3.18, up 123.9% from 2020. The company also established its full year 2021 outlook.

Quest Diagnostics reported a strong first quarter with a 49.3% increase in revenue compared to 2020. The company's base business showed recovery, and contributions from acquisitions and Professional Lab Services relationships accelerated growth.

Quest Diagnostics reported a strong Q4 2020, with revenues up 55.8% compared to 2019. The company's performance was driven by continued high demand for COVID-19 testing. The company has increased its dividend and share repurchase authorization.

Quest Diagnostics reported a strong third quarter, driven by continued demand for COVID-19 testing and a rapid recovery in healthcare utilization. Revenues increased by 42.5% compared to the previous year, with significant growth in diagnostic information services. The company also raised its outlook for the full year 2020.

Quest Diagnostics reported a 6.4% decrease in revenue compared to the previous year, but delivered stronger-than-expected performance due to the expansion of COVID-19 testing. The company has reinstated its full year outlook for 2020.

Quest Diagnostics reported a 3.7% decrease in revenue and a 39.6% decrease in EPS for the first quarter of 2020. The decline was attributed to a material drop in testing volumes in March due to the COVID-19 pandemic. The company has taken actions to protect its financial flexibility, including pay cuts and suspension of certain benefits.

Quest Diagnostics reported record fourth quarter revenues of $1.93 billion, up 4.8% versus 2018. Diluted earnings per share from continuing operations was $1.86, up 101.2% from 2018, and adjusted diluted EPS was $1.67, up 23.7% from 2018.